Please login to the form below
genomes
This page shows the latest genomes news and features for those working in and with pharma, biotech and healthcare.
AbbVie, Biogen and Pfizer collaboration creates new resource for genetic exome sequence analysis
Our hope is that this information will allow researchers to better understand the human genome and identify therapeutic strategies that can specifically target the underlying causes of disease,” he added.
Latest news
-
FDA removes clinical hold on uniQure’s haemophilia gene therapy
Whole genome sequencing of the tumour also confirmed that it had genetic mutations characteristic of HCC, independent of vector integration.
-
bluebird bio says AML case "very unlikely" to be related to gene therapy LentiGlobin
VAMP4 has no known association with the development of AML nor with processes such as cellular proliferation or genome stability.
-
In plain sight
The researchers who raced to sequence the virus’ genome. The Chinese ophthalmologist who tried to warn his colleagues about this novel pneumonia in December 2019.
-
Lilly picks up gene therapy programme in $1bn Prevail Therapeutics acquisition deal
GRN. In November, Lilly signed a deal with Precision BioSciences focused on genome editing research, with an initial focus on developing in vivo therapies for Duchenne muscular dystrophy and two other
-
Lilly links up with Precision BioSciences in genome editing deal
Precision will receive an upfront cash payment of $100m. Eli Lilly has shifted its focus to genome editing following a new research collaboration deal agreed with US-based specialist Precision BioSciences, ... Precision’s ARCUS genome editing platform
FDA removes clinical hold on uniQure’s haemophilia gene therapy
bluebird bio says AML case "very unlikely" to be related to gene therapy LentiGlobin
In plain sight
Lilly picks up gene therapy programme in $1bn Prevail Therapeutics acquisition deal
More from news
Approximately 10 fully matching, plus 168 partially matching documents found.
Latest Intelligence
-
How early-stage clinical research is facilitating the new wave of personalised medicines
Lastly, gene editing is a hugely promising area for new drug development in which DNA is inserted, deleted, modified or replaced in a genome.
-
Patient diversity in clinical trials needs to be centre stage
Around 80% of genome studies are done only on people from a European descendance which is, obviously, quite limited,” he said.
-
The promise of precision medicine
The Biobank’s broad data sets already cover deep phenotyping and whole genome sequencing from 20, 000 individuals, and the Qatar Genome Programme plans to sequence complete genomes of an additional ... treatment. The world- class Sidra Medicine
-
AI and accelerated computing ring in new era for healthcare
With genome analysis toolkits, researchers can sequence and analyse genomes up to 50x faster. ... Hundreds of institutions, including hospitals, universities and supercomputing centres across the world, are using this kind of software to accelerate their
-
Rare genetic diseases – what’s in store for 2021?
Why personalised medicine based on our own genomes is the future of healthcare. ... There have been numerous breakthroughs in recent years, which have made it clear that personalised medicine based on our very own genomes is the future of healthcare.
How early-stage clinical research is facilitating the new wave of personalised medicines
Patient diversity in clinical trials needs to be centre stage
The promise of precision medicine
AI and accelerated computing ring in new era for healthcare
Rare genetic diseases – what’s in store for 2021?
More from intelligence
Approximately 1 fully matching, plus 41 partially matching documents found.
Latest appointments
-
Mark Caulfield departs from Genomics England to take on CEO role at Barts Life Sciences
Caulfield served as chief scientist at Genomics England, working on the 100, 000 Genomes Project. ... First launched in 2012, the 100, 000 Genome Project had ambitious plans to map the genomes of NHS patients to deliver treatments for those with rare
-
Editas Medicine names James Mullen as chairman
He has previously served as CEO of Patheon. Genome editing company Editas Medicine has appointed James Mullen as chairman of the board of directors.
-
Editas Medicine adds to its board of directors
Jessica Hopfield will also serve on the genome editing firm's audit committee. ... Genome editing company Editas Medicine has strengthened its board of directors with the addition of Jessica Hopfield, who will also serve on the board's audit committee.
-
Former GSK CEO joins Synthego’s advisory board
I look forward to contributing to the company’s success as the business extends further into the genome engineering market.”. ... Andrew’s appointment strengthens the company’s position as a leader in genome engineering solutions.”.
-
Paul Stockdale joins Oxford BioDynamics as CFO
A spin-out from Oxford University, Oxford BioDynamics focuses on the discovery and development of epigenetic biomarkers based on regulatory genome architecture.
Mark Caulfield departs from Genomics England to take on CEO role at Barts Life Sciences
Editas Medicine names James Mullen as chairman
Editas Medicine adds to its board of directors
Former GSK CEO joins Synthego’s advisory board
Paul Stockdale joins Oxford BioDynamics as CFO
More from appointments
Approximately 0 fully matching, plus 15 partially matching documents found.
Latest from PMHub
-
Learning about Rare Genetic Disorders on Undiagnosed Children’s Day
The UK has become the first country to take Whole Genome Sequencing, a cutting-edge biotechnology, into mainstream healthcare. ... Rather than looking at the genetic makeup of just the 20, 000 genes known to cause disorders, the whole genome is analysed.
-
Leaders in Pharma: Danielle Portnik
In this episode of Impetus Digital's Leaders in Pharma podcast, I sit down with Danielle Portnik. She is currently the Regional Business Director for International with Ambry Genetics. Address:. Impetus Digital. WaterPark Place. 20 Bay Street, 11th
-
#DemandDiversity: The science behind diversity
3) Another study looked closely at publications that used data from the UK Biobank and the US Health and Retirement Study; these biobanks support genome-wide association studies, which scan data
-
#DemandDiversity: Names erased from history: A dive into black history of clinical research
For example, in all of the Genome-Wide Association Studies used to find mutations linked to cancer, over 80% of participants have been of European descent.
-
Understanding COVID-19 and varying responses across the globe
COVID-19, was first sequenced in Wuhan, China in January 2020. This helped us to identify novel regions of the genome allowing for the development of diagnostic assays to detect the ... As more testing occurs and more data is collected, understanding of
#DemandDiversity: The science behind diversity
#DemandDiversity: Names erased from history: A dive into black history of clinical research
More from PMHub
Approximately 4 fully matching, plus 19 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- EU “still interested” in Valneva COVID vaccine despite UK snub
- US demand for COVID-19 antibody treatments rising fast
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- Havas Life Medicom and ARK lead at 2021 PM Society Digital Awards
- COVID-19 Pfizer/BioNTech booster approved by FDA and CDC
- AstraZeneca invests in RNA tech platform
- Market shaping demands behaviour change
- Healthcare Access and Payment Reform in the US
- Advancing Drug Discovery with Structured and Intelligent Data
- Fishawack Health appoints Elizabeth Landon in the newly created Chief People Officer role
- David Hunt launches independent agency The Considered
- EU “still interested” in Valneva COVID vaccine despite UK snub
- Oxford PharmaGenesis wins Communiqué Medical Affairs Agency of the Year award at Communiqué 2021
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- $47.5m research centre to seek genetic insights into disease
- New data from Moderna supports COVID boosters
PMHub
Wilmington Healthcare
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
